144 related articles for article (PubMed ID: 10630363)
21. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
22. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Ikemura S; Naoki K; Yasuda H; Kawada I; Yoda S; Terai H; Sato T; Ishioka K; Arai D; Ohgino K; Kamata H; Miyata J; Kabata H; Betsuyaku T; Soejima K
Jpn J Clin Oncol; 2015 Apr; 45(4):356-61. PubMed ID: 25612761
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
24. A risk-benefit assessment of irinotecan in solid tumours.
Siu LL; Rowinsky EK
Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
Saito H; Kudoh S; Nakagawa K; Negoro S; Matsui K; Semba H; Takada M
Am J Clin Oncol; 2006 Oct; 29(5):503-7. PubMed ID: 17023787
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Briasoulis E; Samantas E; Kalofonos H; Skarlos D; Makatsoris T; Christodoulou C; Fountzilas G; Bamias A; Dimopoulos MA; Kosmidis P; Pavlidis N
Cancer Chemother Pharmacol; 2005 Nov; 56(5):521-8. PubMed ID: 15959778
[TBL] [Abstract][Full Text] [Related]
27. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
Langer CJ
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):19-24. PubMed ID: 11221017
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
[TBL] [Abstract][Full Text] [Related]
29. Evolving role of irinotecan in small-cell lung cancer.
Spigel DR; Greco FA
Clin Adv Hematol Oncol; 2003 Aug; 1(8):482-5. PubMed ID: 16258436
[TBL] [Abstract][Full Text] [Related]
30. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Masuda N; Fukuoka M; Fujita A; Kurita Y; Tsuchiya S; Nagao K; Negoro S; Nishikawa H; Katakami N; Nakagawa K; Niitani H
Br J Cancer; 1998 Jul; 78(2):251-6. PubMed ID: 9683302
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Kondo R; Watanabe S; Shoji S; Ichikawa K; Abe T; Baba J; Tanaka J; Tsukada H; Terada M; Sato K; Maruyama Y; Makino M; Hirata A; Tanaka H; Koya T; Yoshizawa H; Kikuchi T
Oncology; 2018; 94(4):223-232. PubMed ID: 29444512
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
Fujita A; Takabatake H; Tagaki S; Sekine K
Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan in the treatment of small cell lung cancer.
Masuda N; Fukuoka M
Expert Rev Anticancer Ther; 2001 Aug; 1(2):187-95. PubMed ID: 12113024
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP; Price FV; Bailey H; Gelder M; Rosenbluth R; Durivage HJ; Potkul RK
Cancer; 1998 Jan; 82(2):328-33. PubMed ID: 9445190
[TBL] [Abstract][Full Text] [Related]
36. [Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Couteau C; Armand JP
Bull Cancer; 1998 Dec; Spec No():47-50. PubMed ID: 9932085
[TBL] [Abstract][Full Text] [Related]
37. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
38. Current status of irinotecan in lung cancer.
Fukuoka M
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):6-7. PubMed ID: 11221022
[TBL] [Abstract][Full Text] [Related]
39. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
40. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC.
Choy H; Chakravarthy A; Devore RF; Jagasia M; Hande KR; Roberts JR; Johnson DH; Yunus F
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):43-6. PubMed ID: 10981290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
